Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results
Globe Newswire•06/08/2026•16:01 ET
0
Whiz Insights
Enrollment in soquelitinib registrational Phase 3 relapsed/refractory peripheral T-cell lymphoma (PTCL) and Phase 2 atopic dermatitis trials on track
Soquelitinib’s potential in atopic dermatitis and broader immunology and inflammation indications supported by Phase 1 clinical, immunologic and biomarker data presented at the Society for Investigative Dermatology (SID) annual meeting
Get started
Create a free account to read the full story.